Rickard Jason's Form 4 filing
Ironwood Pharmaceuticals Inc (IRWD) · filed Mar 2, 2022
- Accession no.
- 0001209191-22-014650
- Filed
- Mar 2, 2022
- Trade date
- Feb 28, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $311.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rickard JasonCIK 0001808505 | Officer (SVP, Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −1,913 | $10.77 | −$20,603.01 | 354,162 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −3,150 | $10.77 | −$33,925.5 | 351,012 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −6,022 | $10.77 | −$64,856.94 | 344,990 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −11,057 | $10.77 | −$119,083.89 | 333,933 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −6,820 | $10.77 | −$73,451.4 | 327,113 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.